DYN
Dyne Therapeutics Inc.
$13.44
+$0.31(+2.36%)
57
Overall
60
Value
54
Tech
--
Quality
Market Cap
$1.87B
Volume
2.42M
52W Range
$6.36 - $36.79
Target Price
$35.35
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $58.6M | $150.0M | $171.0M | $242.2M | $343.9M | ||
| Research & Development | $45.2M | $121.3M | $142.8M | $210.8M | $281.4M | ||
| Research Expense | $45.2M | $121.3M | $142.8M | $210.8M | $281.4M | ||
| Selling, General & Administrative | $13.4M | $28.7M | $28.2M | $31.4M | $62.5M | ||
| General & Administrative Expenses | $13.4M | $28.7M | $28.2M | $31.4M | $62.5M | ||
| Salaries & Wages | -- | -- | $15.2M | $48.9M | $63.3M | ||
| Depreciation & Amortization | $700.0K | $1.1M | $1.7M | $1.7M | $1.7M | ||
| Depreciation & Amortization | $700.0K | $1.1M | $1.7M | $1.7M | $1.7M | ||
| Other Operating Expenses | $800.0K | $8.0K | $54.0K | $1.4M | $454.0K | ||
| OPERATING INCOME | |||||||
| Operating income | $-58.6M | $-150.0M | $-171.0M | $-242.2M | $-343.9M | ||
| EBITDA | $-58.3M | $-148.9M | $-165.1M | $-235.3M | $-319.3M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $396.0K | -- | -- | -- | -- | ||
| Intinc | $56.0K | $742.0K | $2.9M | $7.6M | $26.9M | ||
| Net Non-Operating Interest Income/Expense | $-340.0K | $742.0K | $2.9M | $7.6M | $26.9M | ||
| Other Income/Expense | $-450.0K | -- | $-54.0K | $20.4M | $23.0M | ||
| Other Special Charges | $450.0K | -- | -- | $-20.4M | $-23.0M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-58.1M | $-150.0M | $-168.1M | $-235.9M | $-317.4M | ||
| Pre-Tax Income | $-58.5M | $-149.3M | $-168.1M | $-235.9M | $-317.4M | ||
| NET INCOME | |||||||
| Net Income | $-59.4M | $-149.3M | $-168.1M | $-235.9M | $-317.4M | ||
| Net Income (Continuing Operations) | $-59.4M | $-149.3M | $-168.1M | $-235.9M | $-317.4M | ||
| Net Income (Discontinued Operations) | $-59.4M | $-149.3M | $-168.1M | $-235.9M | $-317.4M | ||
| Net Income (Common Stockholders) | $-58.5M | $-149.3M | $-168.1M | $-235.9M | $-317.4M | ||
| Normalized Income | -- | -- | -- | -- | $-314.2M | ||
| TOTALS | |||||||
| Total Expenses | $58.6M | $150.0M | $171.0M | $242.2M | $343.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $14.4M | $50.9M | $52.0M | $59.7M | $94.1M | ||
| Average Shares Outstanding (Diluted) | $14.4M | $50.9M | $52.0M | $59.7M | $94.1M | ||
| Shares Outstanding | $51.5M | $51.6M | $56.3M | $142.3M | $113.1M | ||
| Basic EPS | $-4.13 | $-2.93 | $-3.23 | $-3.95 | $-3.37 | ||
| Basic EPS (Continuing Operations) | $-4.13 | $-2.93 | $-3.23 | $-3.95 | $-3.37 | ||
| Diluted EPS | $-4.13 | $-2.93 | $-3.23 | $-3.95 | $-3.37 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.23 | $-3.95 | $-3.37 | ||
| OTHER METRICS | |||||||
| Other Gand A | $13.4M | $28.7M | $28.2M | $31.4M | $62.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DYN | $13.44 | +2.4% | 2.42M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |